Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report) shot up 9.1% on Tuesday. The company traded as high as $29.73 and last traded at $29.73. Approximately 108,796 shares changed hands during trading, a decline of 87% from the average session volume of 815,535 shares. The stock had previously closed at $27.25.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the stock. Leerink Partners assumed coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They issued an “outperform” rating and a $40.00 price objective for the company. HC Wainwright began coverage on Parabilis Medicines in a report on Thursday, October 22nd. They set a “buy” rating and a $40.00 target price on the stock. Bank of America began coverage on Parabilis Medicines in a research note on Monday, July 6th. They issued a “buy” rating and a $45.00 target price for the company. Guggenheim initiated coverage on Parabilis Medicines in a report on Monday, July 6th. They issued a “buy” rating and a $40.00 price target for the company. Finally, Lifesci Capital raised Parabilis Medicines to a “strong-buy” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.25.
View Our Latest Stock Report on Parabilis Medicines
Parabilis Medicines Stock Up 5.9%
The company has a market capitalization of $3.57 billion and a price-to-earnings ratio of -13.55. The business’s 50-day simple moving average is $32.72.
Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($2.16). The business had revenue of $0.15 million during the quarter. On average, research analysts expect that Parabilis Medicines, Inc. will post -2.60 earnings per share for the current fiscal year.
Institutional Trading of Parabilis Medicines
Institutional investors and hedge funds have recently bought and sold shares of the stock. Sterling Capital Management LLC acquired a new position in shares of Parabilis Medicines during the 3rd quarter worth approximately $35,000. Persistent Asset Partners Ltd acquired a new stake in shares of Parabilis Medicines in the 2nd quarter valued at approximately $113,000. Alyeska Investment Group L.P. acquired a new stake in shares of Parabilis Medicines in the 2nd quarter valued at approximately $274,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Parabilis Medicines in the second quarter valued at $526,000. Finally, WINTON GROUP Ltd bought a new position in shares of Parabilis Medicines in the second quarter valued at $955,000.
About Parabilis Medicines
Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.
Read More
- Five stocks we like better than Parabilis Medicines
- Republic Services Has the Momentum, But Waste Management Has Another Advantage
- Alphabet’s Golden Dome Talks Could Open a New Market, But How Much Is at Stake?
- Tempus AI Surges on Earnings Beat, But Can the Rally Last?
- MicroVision Pivots: Mapping New Ground Beyond Auto
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
